Patents by Inventor Ashish Kalra

Ashish Kalra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20240016928
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: August 1, 2023
    Publication date: January 18, 2024
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20230062425
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: April 1, 2022
    Publication date: March 2, 2023
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • TGF-BETA INHIBITORS AND USE THEREOF
    Publication number: 20230050148
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 16, 2023
    Inventors: Ashish Kalra, Thomas Schurpf, Adam Fogel, Christopher Brueckner, Alan Buckler, Constance Martin, Si Tuen Lee-Hoeflich
  • Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
    Patent number: 11344552
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 31, 2022
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
    Patent number: 11071726
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: July 27, 2021
    Inventors: Jonathan Basil Fitzgerald, Ashish Kalra, Shannon Leonard, Stephan Braun, Bin Zhang
  • Treating Gastric Cancer Using Combination Therapies Comprising Liposomal Irinotecan, Oxaliplatin, 5-Fluoruracil (and Leucovorin)
    Publication number: 20200030302
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: November 1, 2017
    Publication date: January 30, 2020
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Jonathan Basil Fitzgerald, Ashish Kalra, Shannon Leonard, Stephan Braun, Bin Zhang
  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20190209682
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: March 22, 2019
    Publication date: July 11, 2019
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20180207267
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: January 5, 2018
    Publication date: July 26, 2018
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20180078556
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 22, 2018
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20170049775
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 23, 2017
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • NON-INVASIVE IMAGING METHODS FOR PATIENT SELECTION FOR TREATMENT WITH NANOPARTICULATE THERAPEUTIC AGENTS
    Publication number: 20140170075
    Abstract: Methods for providing treatment of pathologic conditions with nanoparticulate therapeutic agents are disclosed. Novel methods for determining liposomal deposition at sites of pathology using non-invasive imaging are also disclosed.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 19, 2014
    Inventors: Daryl C. Drummond, Jonathan B. Fitzgerald, Ashish Kalra, Walid Kamoun, Stephan Klinz